Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline

Eli Lilly (NYSE: LLY) is reportedly in advanced discussions to acquire psychedelic drug developer AtaiBeckley, a move that could significantly strengthen the pharmaceutical giant’s neuroscience portfolio. According to a Bloomberg News report citing people familiar with the matter, the deal could be announced as early as this week.

The Indianapolis-based drugmaker is said to be negotiating an acquisition at a premium to AtaiBeckley’s current market value, which has reached approximately $2 billion after the biotech company’s shares surged more than 100% over the past year.

The potential transaction reflects Lilly’s growing interest in psychedelic-based therapies, an area that has attracted increasing attention as pharmaceutical companies search for new treatments for complex mental health conditions.

Analysts at BMO Capital Markets said the acquisition would provide Eli Lilly with a platform of rapid-acting psychedelic medicines while expanding its presence in treatment-resistant depression (TRD) and other difficult-to-treat psychiatric disorders. The brokerage maintained its "Outperform" rating on Lilly and a $1,300 price target, citing the long-term growth potential of psychedelic therapies as regulatory support continues to improve.

AtaiBeckley is developing innovative treatments for treatment-resistant depression and social anxiety disorder. Its leading drug candidate, BPL-003, is a fast-acting psychedelic nasal spray that has produced encouraging mid-stage clinical trial results and has received the U.S. Food and Drug Administration’s Breakthrough Therapy designation.

In addition to BPL-003, the company’s pipeline includes VLS-01 for treatment-resistant depression and EMP-01 for social anxiety disorder. Analysts believe these programs could provide Lilly with valuable late-stage assets and broaden its pipeline of psychiatric treatments.

The psychedelic medicine sector has gained momentum in recent years, driven by positive clinical data and the commercial success of Johnson & Johnson’s Spravato, an approved therapy for treatment-resistant depression. If completed, the acquisition would position Eli Lilly to capitalize on the growing market for innovative mental health treatments while reinforcing its long-term strategy in neuroscience and psychiatric drug development.